Rapport Therapeutics reported cash from operations of -$41.45M and free cash flow of -$41.53M for the quarter ended Jun 2026, down 65.4% year over year. This cash flow statement covers 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Net Income | -6.41M | -8.71M | -13.52M | -15.28M | -18.12M | -17.54M | -19.98M | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Share-based Compensation | 0.94M | 0.86M | 1.00M | 1.49M | 3.84M | 4.00M | 3.21M | 6.44M | 6.12M | 6.30M | 5.69M | 8.03M | 8.03M |
| Cash from Operations | -5.42M | -10.36M | -17.61M | -16.35M | -16.41M | -14.45M | -20.24M | -25.07M | -17.46M | -24.70M | -13.06M | -41.45M | |
| Depreciation, Depletion & Amortization | |||||||||||||
| Amortizatization of Intangibles | 0.15M | 0.98M | 0.83M | 1.96M | -0.56M | 0.44M | 0.46M | 0.57M | 0.57M | 0.58M | 0.59M | ||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.02M | 0.05M | 0.15M | 0.21M | 0.22M | 0.26M | 0.24M | 0.25M | 0.26M | 0.27M | 0.23M | 0.21M | |
| Change in Working Capital | |||||||||||||
| Change in Receivables | 0.06M | 0.23M | |||||||||||
| Change in Account Payables | 0.63M | 0.72M | -1.13M | 0.09M | 0.05M | 0.65M | 0.18M | 1.03M | -0.18M | 1.18M | 2.31M | -3.68M | |
| Change in Accured Expenses | 1.10M | 3.38M | 0.18M | -0.98M | 0.32M | 0.85M | 0.33M | 0.45M | 1.70M | 3.69M | -3.49M | 14.58M | |
| Other Working Capital Changes | -0.51M | 1.89M | 2.07M | -0.90M | 0.67M | 0.01M | 0.82M | 4.32M | -2.53M | 0.99M | -0.81M | 3.16M | |
| Investing Activities | |||||||||||||
| Capital Expenditures | 0.05M | 1.44M | 1.07M | 0.97M | 0.14M | 0.23M | 0.29M | 0.02M | 0.13M | 0.17M | 0.09M | 0.08M | |
| Change in Acquisitions & Divestments | 3.95M | 32.29M | 56.84M | 116.72M | 64.56M | 35.48M | 44.98M | 22.92M | 58.32M | 65.16M | |||
| Cash from Investing Activities | -0.05M | -78.66M | -41.93M | -107.10M | -53.04M | 31.93M | 21.03M | 22.60M | -56.78M | -174.32M | 37.94M | 25.60M | |
| Financing Activities | |||||||||||||
| Other financing activities | 0.28M | 0.01M | 0.06M | 0.58M | 0.71M | 0.81M | 1.59M | ||||||
| Change in Capital Stock | |||||||||||||
| Net Shares Issued and Repurchased | 2.87M | 1.63M | 2.52M | 1.94M | |||||||||
| Net Equity Issued and Repurchased | 64.00M | -0.09M | |||||||||||
| Misc. | |||||||||||||
| Cash from Financing Activities | 85.36M | -0.14M | 63.66M | 159.35M | -1.39M | 0.01M | 0.01M | -0.06M | 270.53M | 0.31M | 0.53M | 1.41M | |
| Change in Cash | 79.88M | -89.16M | 4.12M | 35.90M | -70.85M | 17.49M | 0.80M | -2.54M | 196.29M | -198.71M | 25.41M | -14.44M | |
| Free Cash Flow | -5.48M | -11.79M | -18.69M | -17.32M | -16.55M | -14.67M | -20.53M | -25.09M | -17.60M | -24.87M | -13.15M | -41.53M | |
| Net Cash Flow | 79.88M | -89.16M | 4.12M | 35.90M | -70.85M | 17.49M | 0.80M | -2.54M | 196.29M | -198.71M | 25.41M | -14.44M |